Literature DB >> 30026294

Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient.

Jian-Ping Zhang1, Rui Zhang2, Shih-Ting Tsao2, Yu-Chen Liu2, Xiaochuan Chen2, Dao-Pei Lu1, Paul Castillo3, Lung-Ji Chang2,4,5.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30026294      PMCID： PMC6058233          DOI： 10.1182/bloodadvances.2018017004

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  17 in total

1.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

Review 2.  Donor-derived CD19-targeted T cells in allogeneic transplants.

Authors:  Chiara Francesca Magnani; Andrea Biondi; Ettore Biagi
Journal:  Curr Opin Hematol       Date:  2015-11       Impact factor: 3.284

3.  Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety.

Authors:  Lu Hao; Tongtong Li; Lung-Ji Chang; Xiaochuan Chen
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

4.  The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.

Authors:  Ronjon Chakraverty; Megan Sykes
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

5.  Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.

Authors:  L-J Chang; X Liu; J He
Journal:  Gene Ther       Date:  2005-07       Impact factor: 5.250

6.  An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens.

Authors:  Bei Wang; Jin He; Chen Liu; Lung-Ji Chang
Journal:  Vaccine       Date:  2006-02-28       Impact factor: 3.641

Review 7.  Biology and clinical application of CAR T cells for B cell malignancies.

Authors:  Marco L Davila; Michel Sadelain
Journal:  Int J Hematol       Date:  2016-06-04       Impact factor: 2.490

Review 8.  Alloantigen presentation and graft-versus-host disease: fuel for the fire.

Authors:  Motoko Koyama; Geoffrey R Hill
Journal:  Blood       Date:  2016-03-30       Impact factor: 22.113

9.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

Authors:  Jennifer N Brudno; Robert P T Somerville; Victoria Shi; Jeremy J Rose; David C Halverson; Daniel H Fowler; Juan C Gea-Banacloche; Steven Z Pavletic; Dennis D Hickstein; Tangying L Lu; Steven A Feldman; Alexander T Iwamoto; Roger Kurlander; Irina Maric; Andre Goy; Brenna G Hansen; Jennifer S Wilder; Bazetta Blacklock-Schuver; Frances T Hakim; Steven A Rosenberg; Ronald E Gress; James N Kochenderfer
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

Review 10.  Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.

Authors:  Assaf Marcus; Zelig Eshhar
Journal:  Expert Opin Biol Ther       Date:  2014-03-24       Impact factor: 4.388
View more
  14 in total

1.  Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain.

Authors:  Xiao Liang; Yong Huang; Dan Li; Xiao Yang; Lin Jiang; Weilin Zhou; Jinhua Su; Nianyong Chen; Wei Wang
Journal:  Gene Ther       Date:  2021-05-06       Impact factor: 5.250

2.  Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.

Authors:  Piriya Luangwattananun; Mutita Junking; Jatuporn Sujjitjoon; Yupanun Wutti-In; Naravat Poungvarin; Chanitra Thuwajit; Pa-Thai Yenchitsomanus
Journal:  Breast Cancer Res Treat       Date:  2021-01-03       Impact factor: 4.872

Review 3.  Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions.

Authors:  Harish Sudarsanam; Raymund Buhmann; Reinhard Henschler
Journal:  Front Bioeng Biotechnol       Date:  2022-06-29

Review 4.  CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.

Authors:  Ezgi Elmas; Noushin Saljoughian; Marcelo de Souza Fernandes Pereira; Brian P Tullius; Kinnari Sorathia; Robin J Nakkula; Dean A Lee; Meisam Naeimi Kararoudi
Journal:  Front Oncol       Date:  2022-04-05       Impact factor: 5.738

Review 5.  Genetically engineered T cells for cancer immunotherapy.

Authors:  Dan Li; Xue Li; Wei-Lin Zhou; Yong Huang; Xiao Liang; Lin Jiang; Xiao Yang; Jie Sun; Zonghai Li; Wei-Dong Han; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2019-09-20

6.  Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia.

Authors:  Hui Zhang; Wen-Ting Gan; Wen-Ge Hao; Peng-Fei Wang; Zhuo-Yan Li; Lung-Ji Chang
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244

7.  Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.

Authors:  Xuan Zhou; Sanfang Tu; Chunsheng Wang; Rui Huang; Lan Deng; Chaoyang Song; Chunyan Yue; Yanjie He; Jilong Yang; Zhao Liang; Anqin Wu; Meifang Li; Weijun Zhou; Jingwen Du; Zhenling Guo; Yongqian Li; Cheng Jiao; Yuchen Liu; Lung-Ji Chang; Yuhua Li
Journal:  Front Immunol       Date:  2020-11-27       Impact factor: 7.561

8.  CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin's Lymphoma.

Authors:  YuanBo Xue; Xun Lai; RuiLei Li; ChunLei Ge; BaoZhen Zeng; Zhen Li; QiaoFen Fu; LiuFang Zhao; SuWei Dong; JinYan Yang; JiYin Guo; QingYin Meng; QingHua Tan; ZhenHui Li; HaiYan Ding; YanLei Zhang; ShaoHui Liu; Alex H Chang; Hong Yao; RongCheng Luo
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

Review 9.  Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.

Authors:  Xinyi Xiao; Shengkang Huang; Sifei Chen; Yazhuo Wang; Qihang Sun; Xinjie Xu; Yuhua Li
Journal:  J Exp Clin Cancer Res       Date:  2021-11-18

Review 10.  Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.

Authors:  Elizabeth L Siegler; Saad S Kenderian
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.